Fig. 2 | Mucosal Immunology

Fig. 2

From: Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition

Fig. 2

HSV-1 mobility in CVM with exogenously added polyclonal anti-HSV-1 IgG (pAb) and monoclonal anti-HSV-1-gD. Comparison of IgG produced in Expi293 cells (mAb-293) and Nicotiana Benthamiana (mAb-N), and non-specific anti-Biotin IgG control. Polyclonal anti-HSV-1 was tested at a final concentration of 5, 1, or 0.5 µg/mL. HSV8-293 and HSV8-N mAbs and non-specific anti-Biotin IgG control tested at 5 µg/mL. a Ensemble-averaged <Deff> and b percent of fast-moving virions as a function of increasing polyclonal anti-HSV-1 concentration. c Ensemble-averaged <Deff> and d percent of fast-moving viruses in CVM treated with mAb-293 and mAb-N vs. pAb. All Ab concentrations are 5 µg/mL. Repeated Measures One-Way ANOVA with multiple comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). N = 28 matched samples (A/B). N = 70 matched samples, collected across six donors (C/D)

Back to article page